Science
EU Approves First CRISPR Gene Therapy for Sickle Cell Disease
European regulators approved the first CRISPR-based gene therapy for sickle cell disease on Wednesday, nearly a year after the treatment won US approval. The decision opens a one-time treatment to patients across Europe and could accelerate access in Africa, where the disease burden is heaviest.
Illustration: Clear News
BRUSSELS (October 14, 2026). The European Medicines Agency approved the first CRISPR gene therapy for sickle cell disease on Wednesday, clearing a one-time treatment that edits a patient's own stem cells to produce healthy hemoglobin.
The therapy, marketed in Europe as HemeCure, is approved for patients ages 12 and older with severe sickle cell disease who are eligible for stem cell transplant but lack a matched donor. The approval follows the treatment's US authorization last October, where it has been administered to more than 200 patients.
Sickle cell disease affects an estimated 100 million people worldwide, with the heaviest burden in sub-Saharan Africa, India, and the Middle East. In Europe, roughly 50,000 people live with the condition, many of them in France, the United Kingdom, and Italy. The disease causes red blood cells to deform into a sickle shape, triggering excruciating pain episodes, organ damage, and shortened life expectancy.
The therapy works by editing a patient's blood stem cells with CRISPR-Cas9 to reactivate fetal hemoglobin, a form of the oxygen-carrying protein that is normally switched off after birth. Fetal hemoglobin does not sickle, and patients with high levels of it typically experience far milder disease. The edited cells are infused back into the patient after chemotherapy clears out the bone marrow.
Clinical trials showed striking results. Among 44 patients followed for at least 16 months, 42 remained free of severe pain crises, the primary measure of success. "The data showed a durable, transformative effect," said Dr. Ingrid Halvorsen, the EMA's lead reviewer for advanced therapies. "For eligible patients, this represents a functional cure."
Cost and access
The central question now is access. In the United States, the therapy is priced at $2.2 million per patient, a one-time cost its maker defends by pointing to a lifetime of hospitalizations and transfusions it may prevent. European pricing negotiations will begin with national health systems in the coming weeks, and analysts expect final prices to land between 1.4 and 1.8 million euros per patient.
Patient advocates welcomed the approval but warned that the price will determine whether the therapy changes lives or merely changes headlines. "A cure you cannot reach is not a cure," said Amara Diallo, president of the European Sickle Cell Federation. "We need reimbursement decisions quickly, and we need a plan for the patients in Africa who need this most."
The manufacturer, Vertex BioGen, said it has opened a Belgian facility to serve the European market and has begun talks with the World Health Organization about tiered pricing for middle-income countries. The first European treatments could begin early next year. The company has also filed to expand the therapy's approval to beta thalassemia, another inherited blood disorder.
Safety monitoring continues. No cases of unexpected off-target editing have been reported in the treated patients, but regulators will require 15 years of follow-up, standard for gene therapies. The EMA's approval includes a post-authorization safety study enrolling at least 100 additional patients.